Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kuros BiosciencesCSBTF 76 3-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates CSBTF with a GF Score™ of 76/100 and a GF Value™ of $47.51 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 223 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 448430.04% on this metric.
The historical rank and industry rank for Kuros Biosciences's 3-Year Dividend Growth Rate or its related term are showing as below:
CSBTF's 3-Year Dividend Growth Rate is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 5.6 * Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences 3-Year Dividend Growth Rate Related Terms>
CSBTF vs ABT, SYK, MDT: 3-Year Dividend Growth Rate Comparison
For the Medical Devices subindustry, Kuros Biosciences's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences 3-Year Dividend Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's 3-Year Dividend Growth Rate distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's 3-Year Dividend Growth Rate falls into.
Kuros Biosciences 3-Year Dividend Growth Rate Calculation
This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Dividend Growth Rate of 0.00% mean?
Kuros Biosciences (CSBTF) has a 3-Year Dividend Growth Rate of 0.00% as of Jun. 2026. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Kuros Biosciences and its competitors. According to the industry distribution chart, Kuros Biosciences ranks #999999 out of 223 companies in the Medical Devices & Instruments industry.
Is Kuros Biosciences' 3-Year Dividend Growth Rate too high?
Kuros Biosciences' current 3-Year Dividend Growth Rate is 0.00%. Based on the distribution chart, Kuros Biosciences ranks #999999 out of 223 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Kuros Biosciences has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' 3-Year Dividend Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #999999 out of 223 companies for 3-Year Dividend Growth Rate. This places Kuros Biosciences in the lower half of its industry. The industry median 3-Year Dividend Growth Rate is 5.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Dividend Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Dividend Growth Rate among Medical Devices & Instruments companies is 5.60, based on 223 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Dividend Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Dividend Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Dividend Growth Rate mean?
A high 3-Year Dividend Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Dividend Growth Rate is the company's three-year average growth of dividend payout. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Dividend Growth Rate is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current 3-Year Dividend Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.51, compared to a current price of $26.99 — trading 43.2% below its estimated fair value. The current 3-Year Dividend Growth Rate is 0.00%. Kuros Biosciences' overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Dividend Growth Rate calculated?
3-Year Dividend Growth Rate is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current 3-Year Dividend Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $26.99 is trading 43.2% below its estimated GF Value™ of $47.51.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
3-Year Dividend Growth Rate: 0.00%
GF Value™: $47.51 vs. price of $26.99 (43.2% below fair value)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
76GF Score
Get the complete analysis for CSBTF
3-Year Dividend Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
